Elliott Jennifer C, Aharonovich Efrat, Hasin Deborah S
Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA.
Department of Psychiatry, Columbia University Medical Center, 180 Ft. Washington Avenue, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA.
Drug Alcohol Depend. 2015 Jun 1;151:115-20. doi: 10.1016/j.drugalcdep.2015.03.012. Epub 2015 Mar 21.
For individuals with HIV, heavy drinking can pose serious threats to health. Some interventions are effective at reducing drinking in this population, but many HIV-infected heavy drinkers also use marijuana or cocaine. Although these drugs have predicted poor alcohol outcomes in other treatment studies, whether this occurs among HIV patients who drink heavily is unknown.
Participants were binge-drinking HIV primary care patients (N=254) enrolled in a randomized trial of three brief drinking interventions over 60 days that varied in intensity. We investigated the relationship of baseline past-year drug use (marijuana-only, cocaine-only, both, neither) to end-of-treatment drinking quantity and frequency. We also evaluated whether the relationship between intervention type and end-of-treatment drinking varied by baseline drug use. Final models incorporated control for patients' demographic and HIV characteristics.
In final models, drinking frequency at the end of treatment did not vary by baseline drug use, but drinking quantity did (X(2)[3] = 13.87, p < 0.01), with individuals using cocaine-only drinking significantly more per occasion (B = 0.32, p < 0.01). Baseline drug use also interacted with intervention condition in predicting end-of-treatment drinking quantity (X(2)[6] = 13.98, p < 0.05), but not frequency, with the largest discrepancies in end-of-treatment drinks per drinking day by intervention intensity among cocaine-only patients.
In general, HIV patients using cocaine evidenced the highest levels of drinking after alcohol intervention. However, these individuals also evidenced the most pronounced differences in end-of-treatment drinking by intervention intensity. These results suggest the importance of more intensive intervention for individuals using alcohol and cocaine.
对于感染艾滋病毒的个体而言,大量饮酒会对健康构成严重威胁。一些干预措施在减少该人群饮酒量方面是有效的,但许多感染艾滋病毒的酗酒者也吸食大麻或可卡因。尽管在其他治疗研究中这些药物预示着酒精治疗效果不佳,但在大量饮酒的艾滋病毒患者中是否如此尚不清楚。
参与者为参加一项为期60天的三种不同强度简短饮酒干预随机试验的艾滋病毒初级护理酗酒患者(N = 254)。我们调查了过去一年基线药物使用情况(仅吸食大麻、仅使用可卡因、两者都用、两者都不用)与治疗结束时饮酒量和饮酒频率之间的关系。我们还评估了干预类型与治疗结束时饮酒之间的关系是否因基线药物使用情况而异。最终模型纳入了对患者人口统计学和艾滋病毒特征的控制。
在最终模型中,治疗结束时的饮酒频率不因基线药物使用情况而有所不同,但饮酒量存在差异(X(2)[3] = 13.87,p < 0.01),仅使用可卡因的个体每次饮酒量显著更多(B = 0.32,p < 0.01)。基线药物使用情况在预测治疗结束时饮酒量方面也与干预条件存在交互作用(X(2)[6] = 13.98,p < 0.05),但与饮酒频率无关,仅使用可卡因的患者中按干预强度划分的每日饮酒量差异最大。
总体而言,使用可卡因的艾滋病毒患者在酒精干预后饮酒水平最高。然而,这些个体在治疗结束时饮酒量因干预强度而产生的差异也最为显著。这些结果表明对同时使用酒精和可卡因的个体进行更强化干预的重要性。